ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
26 Jun 2018 15:55

Trade Risks Start to Impact, as China Biotech Ambitions Grow…

Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...

Logo
135 Views
Share
bullishWuxi Biologics
19 Jun 2018 19:46

Wuxi Biologics Placement - Probably Not a Surprise to Sell Again when Lock-Up Expires

Biologics Holdings is looking to sell 50m shares of WuXi Biologics (Cayman) Inc. (2269 HK) worth about US$500m. Post sale, Biologics Holdings will...

Share
24 Apr 2018 18:50

Ping An Good Doctor IPO Review - Step Aside, Valuation. Solving Problems Come First.

Ping An Healthcare And Techn (1833 HK) is looking to raise about US$1bn from its upcoming IPO and proceeds will be mainly used for business...

Share
bearishSmartkarma
24 Mar 2018 07:08

ECM Weekly Update - Blocks Bigger than IPOs, Videos, Hotels, Education, Banks, Missiles, Biologics..

As the title suggests, its been an exceptionally busy week and since Toh Zhen Zhou is still on a beach in Bali, hence, this weekly by your's...

Logo
193 Views
Share
bullishWuxi Biologics
21 Mar 2018 20:17

Wuxi Biologics Placement - In Time for the Next Lock-Up, Returns Will Probably Not Match Prior Ones

WuXi Biologics (Cayman) Inc. (2269 HK) plans to raise around US$600m through a mix of primary (85%) and secondary (15%) offering. This will be the...

Logo
310 Views
Share
x